GlaxoSmithKline's shares rose Thursday after the healthcare company announced US approval of Breo Ellipta, a treatment for chronic obstructive pulmonary disease (COPD).
Breo Ellipta, once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with COPD, was given the green light from the Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee.
The committee voted that the efficacy and safety data provide substantial evidence to support approval of the medication. The company submitted a new drug application to the FDA for approval of Breo last July.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"We are pleased with the outcome of today's meeting," said President of GlaxoSmithKline Pharmaceuticals, Patrick Vallance.
"COPD is a debilitating and progressive disease. Its symptoms are often severe and can have a huge impact on patients' lives. This positive recommendation is a crucial first step towards making Breo Ellipta available for appropriate COPD patients across the US.
"We look forward to a final decision from the FDA later this year."
RD
